Biliary Atresia Market Forecast 2032: Epidemiology, FDA Approvals, Therapies, Clinical Trials and Companies by DelveInsight | Albireo Pharma, Mirum Pharma

The Biliary Atresia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Biliary Atresia pipeline products will significantly revolutionize the Biliary Atresia market dynamics.

DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Biliary Atresia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Biliary Atresia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Biliary Atresia Market Insights
https://www.delveinsight.com/sample-request/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Biliary Atresia Market Report:
• The Biliary Atresia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In December 2023, Mirum Pharmaceuticals released top-line results from the Phase II EMBARK clinical study of Livmarli (maralixibat) oral solution in patients with biliary atresia. This double-blind, randomized, placebo-controlled trial assessed Livmarli's effectiveness and safety compared to a placebo in biliary atresia patients post Kasai surgery.
• As per the American Liver Foundation, up to 10-20% of infants with BA may have other associated malformations including multiple spleens, abnormal vessels supplying or draining the liver, or heart defects. About 75% of children with BA may eventually need a liver transplant
• According to the National Organization for Rare Disorders, BA occurs in approximately 1 in 10,000 to 15,000 births in the United States. Approximately 400-600 new cases of BA are encountered in the United States each year
• According to Burns J et.al., the prevalence of BA in Europe is approximately 1 in 12,000 births
• Key Biliary Atresia Companies: Albireo Pharma, Mirum Pharmaceuticals, Intercept Pharmaceuticals, and others
• Key Biliary Atresia Therapies: BYLVAY, LIVMARLI, OCA 0.1mg, Maralixibat, Odevixibat, and others
• The Biliary Atresia epidemiology based on gender analyzed that Biliary Atresia is slightly more common in female infants

Biliary Atresia Overview
According to National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) BA is a condition in infants in which the bile ducts-tubes inside and outside the liver-are scarred and blocked. Bile ducts carry bile from the liver to the gallbladder for storage, and to the first part of the small intestine, also called the duodenum, for use in digestion. In infants with BA, bile can't flow into the intestine, so bile builds up in the liver and damages it. The damage leads to scarring, loss of liver tissue and function, and cirrhosis.

Get a Free sample for the Biliary Atresia Market Report:
https://www.delveinsight.com/report-store/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Biliary Atresia Market
The dynamics of the Biliary Atresia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such and others during the forecasted period 2019-2032.
"In October 2020, the United States Food and Drug Administration (USFDA) granted orphan drug status to Mirum Pharmaceuticals' LIVMARLI for the treatment of Biliary Atresia"

Biliary Atresia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Biliary Atresia Epidemiology Segmentation:
The Biliary Atresia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Biliary Atresia
• Prevalent Cases of Biliary Atresia by severity
• Gender-specific Prevalence of Biliary Atresia
• Diagnosed Cases of Episodic and Chronic Biliary Atresia

Download the report to understand which factors are driving Biliary Atresia epidemiology trends @ Biliary Atresia Epidemiological Insights
https://www.delveinsight.com/sample-request/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Biliary Atresia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Biliary Atresia market or expected to get launched during the study period. The analysis covers Biliary Atresia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Biliary Atresia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Biliary Atresia Therapies and Key Companies
• BYLVAY: Albireo Pharma
• LIVMARLI: Mirum Pharmaceuticals
• OCA 0.1mg: Intercept Pharmaceuticals
• Maralixibat: Mirum Pharmaceuticals, Inc.
• Odevixibat: Albireo

To know more about Biliary Atresia treatment, visit @ Biliary Atresia Medications
https://www.delveinsight.com/sample-request/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Biliary Atresia Market Drivers
• Many pharmaceutical companies are continuously researching and innovating the treatment regimens for eradicating the current unmet needs in Biliary Atresia
• The increasing prevalence of Biliary Atresia, for instance, knee pain associated with osteoarthritis, is primarily contributed by the increase in the aging population that will likely impact the market in the near future.

Biliary Atresia Market Unmet Needs
• Challenges in diagnoses
• Development of novel therapies
• Limitations in gene therapy
• Poor disease understanding
• Clinical biomarkers

Scope of the Biliary Atresia Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Biliary Atresia Companies: Albireo Pharma, Mirum Pharmaceuticals, Intercept Pharmaceuticals, and others
• Key Biliary Atresia Therapies: BYLVAY, LIVMARLI, OCA 0.1mg, Maralixibat, Odevixibat, and others
• Biliary Atresia Therapeutic Assessment: Biliary Atresia current marketed and Biliary Atresia emerging therapies
• Biliary Atresia Market Dynamics: Biliary Atresia market drivers and Biliary Atresia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Biliary Atresia Unmet Needs, KOL's views, Analyst's views, Biliary Atresia Market Access and Reimbursement

Discover more about therapies set to grab major Biliary Atresia market share @ Biliary Atresia market forecast
https://www.delveinsight.com/sample-request/biliary-atresia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Biliary Atresia Market Report Introduction
2. Executive Summary for Biliary Atresia
3. SWOT analysis of Biliary Atresia
4. Biliary Atresia Patient Share (%) Overview at a Glance
5. Biliary Atresia Market Overview at a Glance
6. Biliary Atresia Disease Background and Overview
7. Biliary Atresia Epidemiology and Patient Population
8. Country-Specific Patient Population of Biliary Atresia
9. Biliary Atresia Current Treatment and Medical Practices
10. Biliary Atresia Unmet Needs
11. Biliary Atresia Emerging Therapies
12. Biliary Atresia Market Outlook
13. Country-Wise Biliary Atresia Market Analysis (2019-2032)
14. Biliary Atresia Market Access and Reimbursement of Therapies
15. Biliary Atresia Market Drivers
16. Biliary Atresia Market Barriers
17. Biliary Atresia Appendix
18. Biliary Atresia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Absssi Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Acute Ischemic Stroke Ais Market: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
• Acute On Chronic Liver Failure Aclf Market: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
• Adrenal Insufficiency Market: https://www.delveinsight.com/report-store/adrenal-crisis-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Athlete's Foot Market: https://www.delveinsight.com/report-store/athletes-foot-market
• Biliary Atresia Market: https://www.delveinsight.com/report-store/biliary-atresia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Car T Therapy For Acute Lymphoblastic Leukemia All Market: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia

Contact Us:
Ankit Nigam
Marketing Manager
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.